Abstract Number: 0249 • ACR Convergence 2021
Open-label, Long-term (10-year) Study of the Safety of Etanercept in Children with Extended Oligoarticular Arthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis
Background/Purpose: CLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in the…Abstract Number: 1885 • ACR Convergence 2020
Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial
Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…Abstract Number: 542 • 2019 ACR/ARP Annual Meeting
‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…Abstract Number: 552 • 2019 ACR/ARP Annual Meeting
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Background/Purpose: Background: Biosimilar TNFα inhibitors have only become available in the last few years. Etanercept bisosimilar SB-4 Benepali® has been launched in March 2016 in…Abstract Number: 1116 • 2019 ACR/ARP Annual Meeting
Non-medical Switching from Reference to Biosimilar Etanercept – No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data
Background/Purpose: Real-world data about switching patients from originator product to a biosimilars are important to assess and to document the outcome of switches in clinical…Abstract Number: 1443 • 2019 ACR/ARP Annual Meeting
Real World Switching Patterns of Etanercept Original and Biosilmilar in Germany
Background/Purpose: We have previously evaluated switching dynamics between etanercept biologic original (EtnBO) and etanercept biosimilars (EtnBS) over approximately 18 months following the first EtnBS launch…Abstract Number: 1491 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term…Abstract Number: 1505 • 2019 ACR/ARP Annual Meeting
Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Background/Purpose: Ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treatment includes biologics, prescribed on a long-term basis. As persistence data from real-world practice are limited, the…Abstract Number: 2145 • 2019 ACR/ARP Annual Meeting
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Background/Purpose: Tildrakizumab (TIL) is a high-affinity anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to evaluate…Abstract Number: 2382 • 2019 ACR/ARP Annual Meeting
Relationships Between DAS28 Response and Clinical, Functional and Radiographic Outcomes in Year 2 of the COMET Study of Etanercept in Patients with Rheumatoid Arthritis
Background/Purpose: For patients with rheumatoid arthritis (RA) who are treated with etanercept (ETN) plus methotrexate (MTX), dosing down of ETN or withdrawal of MTX are…Abstract Number: 2712 • 2019 ACR/ARP Annual Meeting
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…Abstract Number: 206 • 2019 ACR/ARP Annual Meeting
Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study
Background/Purpose: Clinical trials showed that Etanercept (ETN) is highly effective in reducing clinical disease activity and often leading to remission and radiographic non-progression in patients…Abstract Number: 251 • 2019 ACR/ARP Annual Meeting
Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US
Background/Purpose: Biosimilars have enabled some US institutions and payers to achieve significant financial savings after implementing a formulary change from the reference biologic. However, within…Abstract Number: L11 • 2018 ACR/ARHP Annual Meeting
Etanercept and Methotrexate As Monotherapy or in Combination in Patients with Psoriatic Arthritis: A Phase 3, Double-Blind, Randomized Controlled Study
Background/Purpose: Methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) such as etanercept (ETN) are often prescribed for psoriatic arthritis (PsA) either alone or in combination,…
- 1
- 2
- 3
- …
- 9
- Next Page »